A Single-Center, Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics of Repeat Doses of ARM210 in Healthy Subjects.

2023-509086-20-00 Protocol CL1-210-03 Human pharmacology (Phase I) - Other Ended

Start 13 Feb 2024 · End 3 May 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CL1-210-03

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 8
Countries 1
Sites 1

Cardiac arrhythmias

Key facts

Sponsor
Armgo Pharma Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
13 Feb 2024 → 3 May 2024
Decision date (initial)
2024-02-02
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cardiac arrhythmias

VersionLevelCodeTermSystem organ class
20.0 HLGT 10007521 Cardiac arrhythmias 10007541

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Armgo Pharma Inc.

Sponsor organisation
Armgo Pharma Inc.
Address
777 Old Saw Mill River Road
City
Tarrytown
Postcode
10591-6717
Country
United States

Scientific contact point

Organisation
Armgo Pharma Inc.
Contact name
Gene Marcantonio

Public contact point

Organisation
Armgo Pharma Inc.
Contact name
Rachael Russell

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 8 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-02-13 2024-05-03 2024-02-13 2024-04-16

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-15 Netherlands Acceptable
2024-02-02
2024-02-02